The Interface between Psychiatry and Ophthalmology

Evgenii Sadykov1,3,*, Jan Studnička2, Ladislav Hosák1,3, Mikela-Rafaella Siligardou4, Hajer Elfurjani4, Jessica Leung Hoikam6, Surentheran Kugananthan4, Anastasios Petrovas4, Talal Amjad4

ABSTRACT
Objectives: The aim of this article is to review the interface between psychiatry and ophthalmology at several levels, such as the influence of psychopharmacology on eye disorders, the occurrence of psychiatric symptoms in eye diseases, and the neuroophthalmological examination methods supporting the validity of psychiatric diagnoses.

Materials and Methods: We searched the PubMed computer database for the key words “Psychiatry” and “Ophthalmology” on the 28th of August, 2018 to obtain relevant articles which were consequently summarized.

Results: The results showed that most patients with ocular disease simultaneously have one or more psychiatric symptoms. We also found a prevalence of eye-related side effects in patients who use psychiatric drugs. At the same time, we observed that some ophthalmology methods of diagnostics can be used as diagnostic tools in psychiatry.

Conclusions: Most studies showed a significant relation between psychiatry and ophthalmology, such as eye symptoms and diseases following long-term use of psychotropics as well as psychiatric symptoms and syndromes in patients with eye disorders. Our review may be beneficial to psychiatrists, ophthalmologists, and, last but not least, the patients themselves.

KEYWORDS
depression; eye disease; psychopharmacology; dry eye syndrome; schizophrenia; blepharitis; bipolar disorder; pharmacotherapy

AUTHOR AFFILIATIONS
1 Department of Psychiatry, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
2 Department of Ophthalmology, Charles University, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Czech Republic
3 Department of Psychiatry, University Hospital Hradec Králové, Czech Republic
4 Charles University, Faculty of Medicine in Hradec Králové, Czech Republic
* Corresponding author: Department of Psychiatry, Charles University, Faculty of Medicine in Hradec Králové, Šimkova 870, 500 38 Hradec Králové, Czech Republic; e-mail: evgenii.sadykov@fnhk.cz

Received: 3 March 2019
Accepted: 13 May 2019
Published online: 26 July 2019

Acta Medica (Hradec Králové) 2019; 62(2): 45–51
https://doi.org/10.14712/18059694.2019.104
© 2019 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
INTRODUCTION

Mental disorders can be a manifestation of an organic brain disease – tumor, cyst, inflammatory process, traumatic encephalopathy, cerebral atherosclerosis, etc. The diagnostic of the cerebral process is important for a psychiatrist. Neuroophthalmological methods, with their results frequently reflecting brain pathology, include studies of acuity and field of vision, movements of the eyeballs, pupillary reactions, and the eye fundus. The results of neuroophthalmological diagnostics could potentially influence the psychiatric diagnosis and treatment strategy.

The aim of this article is to review the interface between psychiatry and ophthalmology at several levels, such as the influence of psychopharmacology on eye disorders, the occurrence of psychiatric symptoms in eye diseases, and the neuroophthalmological examination methods supporting the validity of a psychiatric diagnosis. This may be helpful for psychiatrists as well as ophthalmologists, from the clinical and scientific point of view.

MATERIALS AND METHODS

We searched the PubMed computer database for the key words “Psychiatry” and “Ophthalmology” on the 28th of August 2018 to get relevant articles. Afterwards, we summarized their content. We preferred large studies to individual case reports and recent findings to a historical knowledge. Only articles in English were considered for this review.

RESULTS

1. DEPRESSION AND ANXIETY IN OPHTHALMOLOGY

Chiang et al. (2013) conducted a retrospective follow-up observation to estimate the risk of depression and anxiety in patients with blepharitis using nationwide insurance data from 1997 to 2010 in Taiwan to identify annually patients with newly diagnosed blepharitis (N = 9764) and those without the disease (N = 39056). A chi-squared test was used to examine the distributions of baseline demographic characteristics and comorbidities between blepharitis and non-blepharitis patient groups. The results show that the incidence rate of anxiety and depression were (1.67-fold (95% CI = 1.46–1.70) and 1.29-fold (95% CI = 1.18–1.40) respectively) higher in the blepharitis cohort than in the non-blepharitis cohort. It was also higher in women than in men and increased with age in both cohorts (1).

Zhou et al. (2013) studied the prevalence of depression and anxiety symptoms in Chinese patients with glaucoma. The study included 506 patients with glaucoma. In the study the authors used the Hospital Anxiety and Depression Scale (HADS) and the Chinese-version of the Glaucoma Quality of Life-15 questionnaire (CHI-GQL-15). Multiple linear regression analyses were used to identifying the predictors of depression and anxiety. The results showed that in Chinese glaucoma patients the prevalence of depression and anxiety was 16.4% and 22.92%, respectively. The study also showed that independent predictors of anxiety were female gender (P = 0.001), younger age (P < 0.001), moderate and heavy economic burden (P = 0.009; P < 0.001 respectively), and the summary score of the CHI-GQL-15 (P < 0.001). The CHI-GQL-15 summary score (P < 0.001) and the duration of glaucoma (P = 0.019) were significant independent predictors of glaucoma. The authors concluded that, among Chinese patients with glaucoma, the prevalence of depression and anxiety was relatively high (2).

Chen et al. (2015) evaluated the risk of primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG) in depression patients with long-term use of selective serotonin reuptake inhibitors. The authors used data from the National Health Insurance Research Database in Taiwan and identified 26,186 patients with newly diagnosed depression and without preexisting glaucoma. The authors divided the patients into two cohorts. The first cohort included 13,093 patients with one year of serotonin reuptake inhibitors use. The second was a comparison cohort which included 13,093 patients who had never used serotonin reuptake inhibitors. All cohorts included patients > 20 years. The authors used the Kaplan-Meier method for evaluating the incidence of open-angle and angle-closed glaucoma between serotonin reuptake inhibitors and the comparison cohorts. For calculating the differences between the curves, the authors used a long-rank test. It was revealed that the incidence of open-angle and angle-closure glaucoma between the serotonin reuptake inhibitors and comparison cohorts had non-significant differences (long-rank test P = 0.52 for open-angle glaucoma, P = 0.32 for angle-closure glaucoma). Also, the authors concluded that the incidence of open-angle glaucoma in the serotonin reuptake inhibitors cohort was non-significantly higher than that in the comparison cohort (1.51 vs 1.39 per 1000 person-years), with an adjusted hazard ratio of 1.07 (95% CI = 0.82–1.40). The incidence of angle-closure glaucoma in the serotonin reuptake inhibitors was non-significantly lower than that in the comparison cohorts (0.95 vs 1.11 per 1000 person-years), with an adjusted hazard ratio of 0.85 (95% CI = 0.62–1.18). The authors concluded that the risk of primary open-angle and primary closed-angle glaucoma in the Chinese ethnic population in Taiwan does not depend on the long-term use of serotonin reuptake inhibitors (3).

The purpose of the Vaart et al. (2015) study from the University of North Carolina was to analyze the association between dry eye disease and depression and anxiety. The cases of anxiety (ICD-9 code 300, 300.00, 300.01, 300.02), depression (ICD-9 code 311, 296.2x, 296.3x), dry eye disease (ICD-9 code 375.15) and rheumatoid arthritis (ICD-9 code 714.0) were defined according to ICD-9 codes. The authors were interested in the associations between the diagnosis of dry eye disease and each of depression and anxiety. Because of it they separately estimated odds ratio between dry eye and each of the other disease. For estimating the associational ratio the authors used separate logistic regression models. A total of 460,611 patients were screened; 7,207 patients with dry eye were included, as were 20,004 patients with anxiety and 30,100 patients with depression. All patients were over the age of 18.
Separate odds ratios were calculated for dry eye disease, for anxiety, and for depression. The results show the estimated odds ratio between dry eye disease and anxiety was 2.8 (95% CI 2.6–3.0), while the ratio between dry eye disease and depression was 2.9 (95% CI 2.7–3.1). The study identified statistically significant associations between dry eye and the psychiatric diseases of depression and anxiety in a large population study (4).

In another study, to detect at which level of visual impairment psychological symptoms might appear, Palagyi et al. (2016) from Australia evaluated the prevalence and predictors of depressive symptoms in 329 older patients (aged ≥65 years) who were on a waiting list for cataract surgery. For measuring symptoms of depression, the authors used the 5-item Geriatric Depression Scale (GDS-5). Visual disability was assessed by the Catquest-9SF, visual acuity was measured binocularly and was corrected by the high contrast Early Treatment Diabetic Retinopathy Study (ETDRS) and binocular contrast sensitivity was measured by the Mars Letter Contrast Sensitivity Test. All measurements were done at least one month prior to surgery. Following a complete assessment, 94 patients (28.9%) were shown to have depressive symptoms. The depressive symptoms were significantly associated with visual disability (P = 0.020), higher comorbidity score (P = 0.020), and reduced quality of life (P = 0.003). The study demonstrated a high prevalence of depressive symptoms in older persons with cataract. The authors recommended creating an efficient referring system in order to reduce the surgery waiting time and to improve care coordination. This should include the screening and management of depressive signs during the surgery waiting time, which will play a great role in minimizing the negative psychological impacts of a cataract-related loss of vision in this group of patients (5).

Wan et al. (2016) from China assessed the association of depression and anxiety with dry eye disease by conducting a meta-analysis and systematic review that reported the incidence and prevalence of anxiety and depression in patients with dry eye disease versus healthy controls. The authors analyzed 22 studies consisting of 2,980,026 patients. The meta-analyses showed that dry eye disease was associated with an increased prevalence of anxiety (OR = 2.80, 95%, P < 0.00001) and depression (OR = 2.92, P < 0.00001). In patients with dry eye disease, the anxiety score (P = 0.007) and depression score (P < 0.00001) were significantly higher than in controls (6).

3. SCHIZOPHRENIA IN OPHTHALMOLOGY

The review by Gracitelli et al. (2015) showed that most studies on schizophrenia have focused on disturbances in higher-order brain functions associated with the frontal and pre-frontal cortex. However, recently there have been reported abnormalities in low-level sensory processes, such as the visual system. At early stages of the disease, patients report to have visual disturbances in perception. It is the variations in the dopamine and glutamate systems that have been highlighted in the pathophysiology of the disease. Also, the loss of retinal nerve fiber layer thickness has been well established in several neurologic diseases which also involve dopamine and glutamate dysregulation (9). Thirty schizophrenia patients and 30 age-matched controls were studied with spectral-domain optical coherence tomography and it was found that these measurements were reduced in schizophrenia patients. Cortical visual pathways have been described as magnocellular pathways, parvocellular pathways, and koniocellular pathways. Several studies have reported that visual impairment in schizophrenia patients could result from dysfunction in the magnocellular pathway. Tilt After Effects (TAE) in chronic schizophrenia patients were studied using neuroleptic drugs and compared with Parkinson's disease patients (9). It was shown that, if presenting peripheral fine gratings, schizophrenia patients produced results similar to those suffering from Parkinson's. It has been reported that schizophrenia patients make more color discrimination errors than control subjects. Studies concerning eye movements in schizophrenia patients have found reduced pursuit gain, low initial acceleration, and abnormal gain-corrective saccade interactions (9). Schizophrenia is associated with consistent deficits in visual processing in the early stage of the disease. It is therefore possible for ophthalmological assessment to be carried out as a further aid in the diagnosis of schizophrenia (9).

Ascaso et al. (2010) measured the retinal nerve fiber layer (RNFL) thickness by optical coherence tomography in...
10 patients (males - 8, females - 2, mean age 39 +/- 13 years) with schizophrenia. The patients were from the Department of Psychiatry at the Hospital Clinico Universitario in Zaragoza, Spain. All patients had a corrected visual acuity of 20/20 (with a refractive error of +/- 2 spheric diopters) and intraocular pressure < than 18 mmHg. The group of patients was compared with ten age-matched controls. Peripapillary RNFL thickness, optic nerve head (ONH) measurements, macular thickness and volume were measured by optical coherence tomography (OCT) in both the patients and control group. The results showed a statistically significant reduction of the overall RNFL thickness in schizophrenic patients compared with controls (P = 0.047) and reduced peripapillary RNFL thickness in nasal quadrant in schizophrenic patients compared to controls (P = 0.048). No statistically significant differences were observed between schizophrenia patients and the control group with regard to ONH measurements and macular thickness and volume. The authors showed a statistically significant reduction of peripapillary RNFL thickness in schizophrenia patients evaluated by OCT (10).

5. PEDOPSychiatry IN OPHTHALMOLOGY
Cumurcu et al. (2011) measured social phobia and other psychiatric problems in 42 children 8–13 years with strabismus and 47 healthy controls from Turkey. For evaluating social phobias, the authors used the Screen for Child Anxiety Related Emotional Disorders (SCARED). For each child, the researchers used the Children’s Depression Inventory (CDI) and Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Version (Kiddie-SADS-PL). The results showed that social phobia was diagnosed in 8 (19.04%) of the 42 patients with strabismus and in 1 (2.12%) of the healthy controls. Significantly higher were the CDI (P = 0.001) and SCARED (total score (P = 0.004), social phobia (P = 0.0001) and separation anxiety (P = 0.05) scores of strabismus patient than the control group. The authors concluded that there was a relationship between anxiety, depression, social phobia and children with strabismus, as evidenced by their data (13).

Karaman et al. (2016) in Turkey measured the effect of eye trauma on the mental health and quality of life in 20 patients aged 5 to 18 and their parents. For evaluating the quality of life for both parents and children, the authors used the Pediatric Scale of Quality of Life (PedsQL), and for evaluating mental health the Affect Disorders and Schizophrenia Interview Chart for school children, now and lifelong (AFSIC-NL), was used, along with the Child Post-Traumatic Stress Reaction Index (CPTSD-RI). 95% of patients were exposed to penetrating trauma and 1% to blunt. Nine patients were diagnosed with a mental disorder such as major depression (3.15%), posttraumatic stress disorder (3.15%), and generalized anxiety disorder (3.15%) according to AFSIC-NL. The authors found a statistically significant relationship between lens damage or initial visual acuity and the PedsQL-parent emotional functional scale. Also, the parents of patients had a mild posttraumatic stress disorder regarding the CPTSD-RI. The authors concluded that eye trauma can lead to the development of psychopathology in children (14).

Ikeda et al. (2013) evaluated the incidence of ophthalmologic disorders in 154 (79% male and 21% female) children with autism from the USA, all examined between 1998 and 2006. For analyzing the data, the authors used a SPSS statistical program. The subgroups of patients in the autistic spectrum were: 44.16% mild to moderate autism, 20.13% pervasive developmental disorder, 13.64% autism spectrum disorder, 11.04% severe autism, 7.14% moderate to severe autism, 3.25% Asperger’s, 0.64% Rett syndrome. The findings showed that children with autism had as
follows: no ophthalmic problem (N = 61, p = 0.002), strabismus (N = 32, p = 0.001), amblyopia (N = 16, p = 0.127), refractive error (N = 44, p = 0.044). No relation was found with autism for children who had a history of prematurity gestation (<37 weeks). The findings suggest that ophthalmologic disorders were common in children with diagnoses in the autism spectrum (15).

Black et al. (2013) made a retrospective chart review of ocular abnormality in 44 patients (3:1 males to females, ages ranging 2 to 20 years) diagnosed with autism spectrum disorder (ASD) between January 2007 and October 2011 in the Greater Baltimore Medical Center (GBMC), USA. The results of the review showed that 52% (23) of patients with ASD at GBMC had some sort of ocular abnormality: strabismus 41% (18), significant refractive error 27% (12), anisometropia 7% (3), and amblyopia 11% (5). The authors found that the prevalence of amblyopia, anisometropia, and strabismus were higher among patients with ASD seen at the GBMC pediatric-ophthalmology practice than in the general population (16).

6. GERONTOPSYCHIATRY IN OPHTHALMOLOGY

Su et al. (2016) investigated the association between primary open-angle and primary angle-closure glaucoma with the risk of dementia in 6509 patients with glaucoma (3034 with open-angle and 3025 with angle-closure glaucoma) and a comparison cohort of 26,036 individuals without glaucoma and dementia in Taiwan. For evaluating the risk of dementia, univariate and multivariate Cox proportional hazard models were used. The research showed a higher risk of dementia in patients with glaucoma than in individuals without glaucoma (HR = 1.13, 95%, CI = 1.01–1.27). The patients with open-angle glaucoma had a 1.21-fold increased risk of dementia compared with the individuals without glaucoma (HR = 1.21, 95%, CI = 1.02–1.43). On the other hand, the patients with angle-closure glaucoma were not significantly associated with an increased risk of dementia compared with the healthy individuals (HR = 1.09, 95%, CI = 0.95–1.26). Patients aged ≥65 years with open-angle glaucoma were significantly associated with an increased risk of dementia compared to the healthy individuals (HR = 1.28, 95%, CI = 1.07–1.54). The authors concluded that patients with open-angle glaucoma were significantly associated with an increased risk of dementia compared with healthy individuals but not those with angle-closure glaucoma (17).

7. PSYCPHOPHARMACOLOGY IN OPHTHALMOLOGY

A medical case report by Sears et al. (2015) suggested that long-term use of chlorpromazine can induce conjunctival secondary bilateral melanosis with unilateral limbal tumor (18). Chlorpromazine can also cause pigmentary or granular retinosis, benign natured pigmented segregation on the lens or cornea as well as corneal edema (Sonmez and Aykan 2014) (19). Another case report by Karadaget al. (2015) indicated that the use of the antipsychotic drug aripiprazole can cause an acute transient bilateral myopia. However, the effect was reversed when patients replaced the drug (20). Similarly, Costagliola et al. (2008) suggested the use of SSRIs would increase intraocular pressure, induce optic nerve head changes, and predispose patients to angle closure, but this is dependent on each patient’s individual tolerability of SSRIs (21). Additionally, SSRIs also affects the pupil diameter, aqueous humor dynamics, and optic nerve blood flow. In the review of Sonmez and Aykan (2014), a list of typical psychiatric drugs and their ocular side effects were described. These consist of thioridazine, butyrophenones, TCAs, benzodiazepines, mood stabilizers, lamotrigine, topiramate, and lithium. The side effects include retinitis pigmentosa, visual impairment, accommodation disorder, various eye movements disorder, nystagmus, and even ocuolgyric crisis (19).

The study of Borovik et al. (2009) refers to a case of a 55-year old female with a history of schizophrenia, depression, hypothyroidism, gastro-esophageal reflux and back pain. She was being treated with high dose of clozapine for 16 years and her cumulative dose was 4.67 kg, lithium carbonate 500 mg daily, thyroxine 100 μg daily and omeprazole 20 mg daily. She presented with bilateral pigmentary changes in her cornea and retina and stellate cataract. Clozapine is recommended in patients who experience pigmentary changes from chlorpromazine use, changes which are expected to resolve. The reason phenothiazine-related ocular changes happen is not known, but it is suspected to be related to photosensitization of tissues in which the drug has accumulated after sun exposure or that they alter the dopaminergic regulation of melanotin, which is suspected to increase the susceptibility of photoreceptors to damage by light. In this patient, it may be possible that these changes were produced by the high doses of clozapine, which also acts on dopamine receptors, since none of her other medications are known to have any such side effects (22).

The study of Emoto et al. (2011) was conducted to see whether psychotropic cessation in patients with drug-induced blepharospasm improves motor symptoms. Part or all of the patients’ psychotropic medication was withdrawn and their motor symptoms using the Jankovic rating scale were assessed. Twelve patients were sampled where psychotropics were administered before the onset of blepharospasm in all patients. The mean duration of treatment ranged between 3 and 120 months. At initial presentation, the Jankovic rating scale was 3 in eleven patients and 2 in one patient. After the cessation of medication, blepharospasm improved in all cases within 2 months. Therefore, it was concluded that blepharospasm was directly caused by the psychotropic agents (23).

Stein et al. (2015) measured the risk of open-angle glaucoma and bupropion use in 638,481 patients ≥35 years with no pre-existing open-angle glaucoma. For assessing the impact of bupropion and other antidepressant medications on the risk of open-angle glaucoma, the authors used the multivariable Cox regression modelling. The results showed that open-angle glaucoma developed in 15,292 patients (2.4%). Each additional month of bupropion use was associated with a 0.6% reduced risk of open-angle glaucoma (P = 0.007) after adjustment for use of other antidepressant medication. Patients with 24–48 months of bupropion use had a 21% reduced hazard (P = 0.0099) of open-angle glaucoma compared to non-users. The study
showed that the development of open-angle glaucoma was not significant associated with using selective serotonin reuptake inhibitors (P = 0.39) and tricyclic antidepressants (P = 0.95). The authors concluded that bupropion use may be beneficial in reducing the risk of open-angle glaucoma (24).

In a cross-sectional observational study by Acan et al. (2016), the authors aimed to determine the influence of selective serotonin reuptake inhibitors (SSRIs) on ocular surface and tear film stability. 36 patients (Group 1) and 36 healthy volunteers (Group 2) were enrolled (25). Group 1 was composed of patients in clinical remission of depression and/or anxiety to exclude the possible effect of the psychiatric disease on ocular disease when patients were using SSRIs. Other exclusions included subjects with other psychiatric or systemic disease, the usage of medication or contact lenses, pregnancy, lactation or ocular disease history for the past 12 months. Both Group 1 and 2 underwent detailed psychiatric and ophthalmological examination. The results showed no significant differences between the groups in terms of age and sex (P > 0.05) (25). The most commonly used SSRI among Group 1 was fluoxetine and the period of usage ranged between 2 and 120 months. It is not clearly seen whether the psychiatric disease or the medication used for its treatment were associated with the development of dry eye symptoms. Antidepressants could induce dry eye disease, as most of them inhibit amine (norepinephrine and serotonin) reuptake pumps, thus increasing functional amine-dependent synaptic transmission. In addition, serotonin receptors have been identified in the corneal and conjunctival epithelia, meaning that altered concentrations of serotonin by the use of SSRIs could affect the eyes (25).

Three cases of intraoperative floppy-iris syndrome (IFIS) were reported by Matsuo et al. (2016) during cataract surgery in patients using long-term antipsychotic drugs but without a history of selective α1 blockers (26). IFIS is a complication that may occur during cataract extraction in certain patients. This syndrome is characterized by a flaccid iris which billows in response to ordinary intraocular fluid currents, a propensity for this floppy iris to prolapse towards the area of cataract extraction during surgery, and progressive intraoperative pupil constriction despite standard procedures to prevent this (27). The first case refers to a 39-year old male with chronic angle-closure glaucoma who was being treated for schizophrenia with several classes of antipsychotic drugs, including haloperidol, chlorpromazine, aripiprazole, olanzapine, quetiapine, risperidone, and blesanerin for more than 7 years and topical β-blocker timolol for the glaucoma. In the second case, a 63-year old female was being treated for schizophrenia for more than 10 years with aripiprazole, quetiapine, and risperidone and the topical αβ-blocker levobunolol to treat glaucoma. In the last case, a 65-year old male had a history of haloperidol use for more than 10 years for an organic mental disorder and the topical β-blocker timolol for the treatment of glaucoma, as in case 1 (26). There are also 5 more cases reported in the literature with use of long-term chlorpromazine, risperidone, and quetiapine. All three cases presented with incomplete IFIS, no history of selective α1-blocker for glaucoma, and antipsychotic drug use. Even though antipsychotic drug related IFIS is not common, it seems that any class of antipsychotic drugs can cause such problems as they all have antagonistic effects on acetylcholine, histamine, and α-adrenergic receptors as side effects. Surgeons should take heed of this (26).

DISCUSSION AND CONCLUSION

An ophthalmological examination is part of the complex somatic and paraclinical examination of patients suffering from mental disorders. From previous articles, we can recognize the close relationship between psychiatry and ophthalmology. Unfortunately, only a small number of physicians examine their patients for side effects of psychotropic and ophthalmology drugs or level of anxiety before surgery. The possible value of ophthalmological symptoms and findings for a diagnosis and treatment of mental diseases is determined by the close anatomical and functional connection of the eye and the brain, by the commonality of their vascular system, and a high perceptibility of the eye to the side effects of psychotropic drugs. In an outpatient setting, neuroophthalmological examinations can be easily performed because they are usually cheap, quick, non-invasive, painless and widely available.

Most of the reviewed studies showed a significant relation between psychiatry and ophthalmology, such as eye symptoms in mentally ill subjects, mental problems accompanying eye diseases, and significant adverse side effects of psychotropics on the eye. Psychiatrists should be able to recognize signs and symptoms of eye disorders in people with mental problems, and ophthalmologists should be skilled enough to recognize symptoms of psychiatric disorders in their patients. An early recognition of symptoms in these two fields of medicine can help to start an adequate complex therapy and increase the quality of life of psychiatric as well as ophthalmological patients.

CONFLICT OF INTEREST STATEMENT

The authors declare they have no conflicts of interest.

ACKNOWLEDGEMENTS

Sponsored by the Ministry of Health of the Czech Republic, Czech Health Research Counsil, research grant AZV MZ ČR 16-27243A.

REFERENCES